Los Angeles Capital Management LLC Has $1.10 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Los Angeles Capital Management LLC lowered its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 44.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,528 shares of the company’s stock after selling 44,473 shares during the quarter. Los Angeles Capital Management LLC owned 0.08% of Kiniksa Pharmaceuticals worth $1,098,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KNSA. China Universal Asset Management Co. Ltd. lifted its position in shares of Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares during the period. Franklin Resources Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after purchasing an additional 1,100 shares in the last quarter. New York State Common Retirement Fund lifted its position in Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock worth $302,000 after purchasing an additional 1,680 shares during the period. Quarry LP acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth $50,000. Finally, Martingale Asset Management L P increased its holdings in Kiniksa Pharmaceuticals by 6.8% in the 3rd quarter. Martingale Asset Management L P now owns 48,460 shares of the company’s stock valued at $1,211,000 after buying an additional 3,083 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA opened at $20.28 on Friday. The stock has a market cap of $1.46 billion, a PE ratio of -144.85 and a beta of 0.32. The business has a fifty day moving average of $19.65 and a two-hundred day moving average of $22.50. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.35 earnings per share. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,092 shares of company stock valued at $745,589. 54.57% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.